Astellas Pharma Europe Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Astellas Pharma Europe Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011784
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Astellas Pharma Europe Ltd (Astellas Pharma), a subsidiary of Astellas Pharma Inc is a manufacturer and distributor of drug products. The company provides pharmaceutical drugs in the areas of oncology, transplantation, urology, anti-infective, pain management and dermatology. It also provides discovery and development of new medicines and produce wide range of established products. Astellas Pharma conducts research and development of drug products. The company operates through its drug discovery research center in Japan. It operates in Iceland, Ireland, South Africa, Portugal, Spain, Norway, Denmark, Belgium, the Netherlands, Germany, Switzerland, Hungary, Serbia, Italy, Turkey, France, Romania, Ukraine, Russia, the UAE and the UK, among others. Astellas Pharma is headquartered in Chertsey, the UK.

Astellas Pharma Europe Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
MediGene Completes Sale Of European Rights For Eligard To Astellas 10
Licensing Agreements 12
Optimer Pharma Enters Into Licensing Agreement With Astellas Pharma Europe For Fidaxomicin 12
Astellas Pharma Europe Expands Its Licensing Agreement With TOLMAR For Eligard 14
Asset Transactions 15
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 15
Astellas Pharma Europe Ltd – Key Competitors 16
Astellas Pharma Europe Ltd – Key Employees 17
Astellas Pharma Europe Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Astellas Pharma Europe Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
MediGene Completes Sale Of European Rights For Eligard To Astellas 10
Optimer Pharma Enters Into Licensing Agreement With Astellas Pharma Europe For Fidaxomicin 12
Astellas Pharma Europe Expands Its Licensing Agreement With TOLMAR For Eligard 14
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 15
Astellas Pharma Europe Ltd, Key Competitors 16
Astellas Pharma Europe Ltd, Key Employees 17
Astellas Pharma Europe Ltd, Subsidiaries 18

★海外企業調査レポート[Astellas Pharma Europe Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PricewaterhouseCoopers International Limited:企業の戦略・SWOT・財務情報
    PricewaterhouseCoopers International Limited - Strategy, SWOT and Corporate Finance Report Summary PricewaterhouseCoopers International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Toppan Printing Co Ltd:企業のM&A・事業提携・投資動向
    Toppan Printing Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Toppan Printing Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • EL Sewedy Electric Co (SWDY):電力:M&Aディール及び事業提携情報
    Summary EL Sewedy Electric Co (ELSE) is an integrated energy solutions company. It manufactures and supplies power cables, wires, insulators, transformers, terminators, joint accessories, meters and systems, telecom cables and accessories, fiber optic cables and accessories, wind blades, wind towers …
  • BioLineRx Ltd (BLRX)-医療機器分野:企業M&A・提携分析
    Summary BioLineRx Ltd (BioLineRx) is a clinical stage biopharmaceutical company that focuses on the identification, in-licensing, and development of products to address unmet medical needs. The company’s product pipeline includes BL-8040, a short peptide for multiple cancer and hematological indicat …
  • Comstock Resources Inc (CRK):企業の財務・戦略的SWOT分析
    Summary Comstock Resources Inc (Comstock) is an oil and gas company. It acquires, develops, explores and produces oil and natural gas properties. The company provides oil and gas operations such as Eagle ford Shale, Haynesville Shale and Bakken Shale in North Dakota and Montana; and North Louisiana, …
  • Mediware Information Systems Inc-製薬・医療分野:企業M&A・提携分析
    Summary Mediware Information Systems Inc (Mediware) is a healthcare solutions company that designs, develops and commercializes specialized healthcare software. It provides software to healthcare and human service providers and payers. The company’s portfolio of solutions are equipped in blood banks …
  • Ondine Biomedical Inc:企業の製品パイプライン分析2018
    Summary Ondine Biomedical Inc (Ondine), formerly Ondine Biopharma Corp, a subsidiary of 0902337 B.C. Ltd, is a non-antibiotic anti-infective therapies developer for bacterial, viral, and fungal infections. The company’s products include periowave systems, MRSAid systems, sinuwave systems, exelume sy …
  • NEX Group plc. (IAP):企業の戦略的SWOT分析
    NEX Group plc. (IAP) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Sennebogen Maschinenfabrik GmbH:企業の戦略・SWOT・財務情報
    Sennebogen Maschinenfabrik GmbH - Strategy, SWOT and Corporate Finance Report Summary Sennebogen Maschinenfabrik GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Health Care Service Corp:企業の戦略的SWOT分析
    Health Care Service Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Rockcastle Global Real Estate Co Ltd:企業の戦略・SWOT・財務情報
    Rockcastle Global Real Estate Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Rockcastle Global Real Estate Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Dassault Aviation SA (AM):企業の財務・戦略的SWOT分析
    Dassault Aviation SA (AM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Cedars-Sinai Medical Center-医療機器分野:企業M&A・提携分析
    Summary Cedars-Sinai Medical Center (Cedars-Sinai), formerly Kaspare Cohn Hospital is an academic and medical center that provides healthcare services for patients and medical professionals, and research and education services. The center offers treatments for various conditions such as abdominal pa …
  • U.S. Bancorp:戦略・SWOT・企業財務分析
    U.S. Bancorp - Strategy, SWOT and Corporate Finance Report Summary U.S. Bancorp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • University of Florida-製薬・医療分野:企業M&A・提携分析
    Summary University of Florida (UF) is an educational institute that offers undergraduate, graduate and distance learning programs. The institute offers educational programs in areas of agricultural, business administration, journalism and communications, law, dentistry, arts and sciences, medicine, …
  • Verona Pharma Plc (VRP)-製薬・医療分野:企業M&A・提携分析
    Summary Verona Pharma Plc (Verona Pharma) is a clinical-stage biotechnology company, which focuses on the research, discovery and development of first-in-class therapeutic drugs for the treatment of chronic respiratory and inflammatory diseases. The company's lead candidate, RPL554 is a bronchodilat …
  • Marksans Pharma Ltd (MARKSANS):製薬・医療:M&Aディール及び事業提携情報
    Summary Marksans Pharma Ltd (Marksans Pharma) is a pharmaceutical company that develops, manufactures and markets branded formulations and generic products. The company manufactures non-sterile liquids, ointments and powder products. It offers solid oral dosage in form of tablets, hard gelatin capsu …
  • Fluxion Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary Fluxion Biosciences Inc (Fluxion) is a provider of analytical and live cell analysis tools. The company’s products include IsoFlux system and CTC kits, BioFlux System, IonFlux System, Cytation CTC imager and enumeration kits, and sequencing kits. It provides analytical services for a range o …
  • Forendo Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Forendo Pharma Ltd (Forendo Pharma) is a drug development company that concentrates on tissue specific regulation of sex hormone effects. The company’s product pipeline include fispemifene, which is in clinical phase II development and intended for the treatment of lower urinary tract sympto …
  • Centrais Eletricas do Para SA (CELP5):電力:M&Aディール及び事業提携情報
    Summary Centrais Eletricas do Para SA (CELPA), a subsidiary of Equatorial Energia SA is an electric utility that supplies and distributes power and electricity. The utility offers services such as electric metering, online bill payment, surge protection, outage reporting, energy saving tips, rebates …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆